Cellectar Biosciences Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Good afternoon [to you all], and I thank you for your interest in Cellectar Biosciences and this presentation. I'd also like to thank the Oppenheimer team for their invitation to participate in this conference. Cellectar is traded on the NASDAQ exchange under the ticker symbol, CLRB. Here, you can see the obligatory Safe Harbor statement. Of course, I also direct you to our SEC filings.
On slide 3, you can view the presentation topics. Today, I will provide a general overview with a focus on our lead asset, Iopofosine, which you may know as CLR 131. The focus will be on our hematologic malignancy programming. For background, Cellectar is focused on the development of orphan and ultra-orphan adult and pediatric indications. Indications that we believe the Company can compete and win both in the clinic as well as on the market. The foundation of this focus remains our PLE cancer-targeting platform.
Our lead product is Iopofosine, a small-molecule targeted radiotherapeutic, which combines the PLE targeting platform
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |